Leaderboard
Anzeige
medline.ch
En
|
De
Impressum
Sie sind hier:
Gastroenterologie
»
Magen-Darm
»
Entzündliche Darmerkrankungen
12. Juli 2026
Suchen
medline.ch
Entzündliche Darmerkrankungen
Erweiterte Suche
Dermatologie
Endokrinologie
Ernährung
Gastroenterologie
Gallenwege
Leber
Magen-Darm
Diarrhoe
Entzündliche Darmerkrankungen
Funktionelle Beschwerden
Gastroenteritis
Gastrointestinale Hämorrhagie
Neoplasie
Peptische Ulzera
Anderes
Oesophagus
Pankreas
Gynäkologie
Hämatologie
Infektiologie
Kardiovaskuläre Erkrankungen
Muskuloskelettale Erkrankungen
Neurologie
Onkologie
Ophthalmologie
ORL
Pädiatrie
Psychiatrie
Respirationstrakt
Sportmedizin
Urologie-Nephrologie
Schrift:
Rect Top
Anzeige
Seite 1 von 2912
Artikel 1 - 20 / 58226
Granulocyte and monocyte adsorptive apheresis for ulcerative colitis: mechanisms, clinical evidence, and future perspectives.
Ann Gastroenterol
Tanaka T, Yoshifuku Y, Teshima H, Konishi H, Nakata K, Kitamura K, Otabe N, Mori T, Cho S, Nonaka M, Fujimoto Y.
PMID: 42434156 [PubMed]
Erratum: Comments on "Association between early crohn's disease (CD) diagnosis and development of clinical complications in adults at King Abdulaziz University Hospital".
Ann Med Surg (Lond)
PMID: 42433810 [PubMed]
Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn's disease.
Front Immunol
Wang X, Li J, Yu K, Wu X, Luo Q.
PMID: 42433375 [PubMed - in process]
Correction to: P0562 Comparative Efficacy and Safety of Upadacitinib Versus Oral Prednisolone for the Induction of Remission in Ulcerative Colitis: A Prospective, Multicenter, Open-label, Randomized Controlled Trial (PREDUPA Trial) Protocol and P0563 Mirikizumab Demonstrated Sustained and Durable Long-Term Efficacy and Favorable Safety in Week 52 Endoscopic Responders with Crohn's disease: 3-year VIVID-2 Open-Label Extension Interim Results.
J Crohns Colitis
PMID: 42433038 [PubMed - in process]
Risk of Infections With Infliximab vs Adalimumab Among Children With Inflammatory Bowel Disease.
JAMA Netw Open
Lyu N, Tracy M, Schneeweiss S, Savage TJ.
PMID: 42430170 [PubMed - indexed for MEDLINE]
Redefining Neutrophil Function in Inflammatory Bowel Disease: From Tissue Injury to Immune Resolution.
Mol Biol Rep
Khademi M, Kazemifard N, Ghavami SB, Farmani M, Shahrokh S.
PMID: 42429844 [PubMed - indexed for MEDLINE]
Sialidase inhibitor modulates gut microbiota and enhances mucosal protection in the treatment of ulcerative colitis.
mSystems
Zhao Y, Chen L, Li C, Xu Y, Huang J, Chen S, Yu Z, Liu X.
PMID: 42429666 [PubMed - as supplied by publisher]
Comparative efficacy of advanced therapies in biological-exposed ulcerative colitis - a network meta-analysis of randomized trials.
Eur J Gastroenterol Hepatol
Giri S, Kulkarni A, Harindranath S, Malakar S, Jena A, Joshi H, Nath P.
PMID: 42429193 [PubMed - as supplied by publisher]
Short-chain fatty acids in ulcerative colitis: integrating metabolic fate, dynamic biomarkers, and precision delivery.
Front Nutr
Ying Z, Tian M, Huang X, Ping G, Jiang C.
PMID: 42428604 [PubMed]
Systematic review and network meta-analysis of integrated traditional Chinese and conventional medicine for ulcerative colitis.
Front Pharmacol
Li X, Sha Z.
PMID: 42428503 [PubMed]
Efficacy and safety of ustekinumab in Asian patients with moderately to severely active Crohn's disease: a small subpopulation analysis of UNITI/IM-UNITI long-term extension through 5 years.
Intest Res
Ye BD, Sugimoto K, Cheon JH, Gasink C, Imai Y, Wahking B, Zhuo J, Kawamura S, Hibi T.
PMID: 42427284 [PubMed - as supplied by publisher]
Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North study.
Intest Res
Hisamatsu T, Fujii T, Nakase H, Matsuoka K, Saruta M, Kobayashi T, Inoue S, Toriyama K, Wang D, Uchikawa Y, Fujimoto G, Hibi T.
PMID: 42427283 [PubMed - as supplied by publisher]
Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group.
Aliment Pharmacol Ther
Young D, Booker C, Samaan M, Kok K, Donovan F, Hart A, Batchelor J, Limdi J, Bodger K, Cummings JRF, UndieS study group.
PMID: 42426976 [PubMed - as supplied by publisher]
Comment on "Dose-dependent efficacy and safety of Filgotinib in moderate to severe Crohn's disease: a grade-assessed systematic review and meta-analysis of randomized controlled trials".
Eur J Clin Pharmacol
Laskar TT, Borah S, Arora M.
PMID: 42426347 [PubMed - in process]
Small bowel obstruction secondary to Strongyloides stercoralis: a rare cause and mimic of inflammatory bowel disease.
BMJ Case Rep
Malkopoulos A, Subhaharan D, Kamal S, Haig A.
PMID: 42425604 [PubMed - indexed for MEDLINE]
Two trials with two different answers: potential for Bayesian re-analysis in a Crohn's disease clinical trial.
Gastroenterology
César da Silva B, Noor NM.
PMID: 42425310 [PubMed - as supplied by publisher]
Rising Burden and Clinical Impact of Metabolic Syndrome in Inflammatory Bowel Disease: A Real-World Cohort Study.
United European Gastroenterol J
Tariq R, Parmar K, Desai M, Sterling RK, Sanyal AJ.
PMID: 42424118 [PubMed - indexed for MEDLINE]
Integrative single-cell transcriptomics and mendelian randomization identifies BTN3A2 as a shared protective factor in Behçet's disease and inflammatory bowel disease.
Front Immunol
Dai Q, Wu Y, Geng W, Li M, Zhang W, Lai Y, Zhang P, Zhou C, Wang Y, Cao Q, Luo X, Lai Y, Huang C, Yang P.
PMID: 42421947 [PubMed - indexed for MEDLINE]
Comparison of six nutritional screening tools for identifying BMI‑defined malnutrition in patients with Crohn's disease: a cross‑sectional study.
BMC Gastroenterol
Yu Z, Duan R, Liu Q, Mei W, Chen D, Pan T, Chen Y, Kong F, Ding C.
PMID: 42420858 [PubMed - as supplied by publisher]
Off-label upadacitinib 60Â mg daily in the rescue of refractory ulcerative colitis: an open-labeled cohort study.
J Crohns Colitis
Gu B, Kariyawasam V, Leong RW.
PMID: 42418656 [PubMed - in process]
Artikel 1 - 20 / 58226
Seite 1 von 2912
Rect Bottom
Anzeige
Adserver Footer
Zeitfenster
--unbegrenzt--
1 Woche
1 Monat
3 Monate
6 Monate
1 Jahr
2 Jahre
3 Jahre
5 Jahre
10 Jahre
Sky right 1
Anzeige
Mediscope AG E-mail:
info@mediscope.ch
Disclaimer
|
Datenschutzerklärung / Privacy Policy
|
Werbung